Drug Database · Clinicians

Atorvastatin + Ezetimibe

Brands (11) Liptruzet, Atoreze, Avamed…Show all

Lipid modifying agents; HMG CoA reductase inhibitor in combination with other lipid modifying agent; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug16 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated US FDA label

    Kidney dosing: Atorvastatin (single-agent)
    Show full dosing details
    eGFR ≥60
    No adjustment (label).
    eGFR 30–59
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    eGFR 15–29
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    eGFR <15 (not on dialysis)
    No adjustment (label). Monitor for myopathy. KDIGO: atorvastatin 20 mg/day is the studied dose in CKD G3a–G5; higher doses not proven safe in CKD.
    Hemodialysis (intermittent)
    No dose adjustment (not dialyzed; label). KDIGO: do not start a statin in most patients already on dialysis; continue if already taking one at dialysis initiation.
    Peritoneal dialysis
    No label adjustment; no PD data.
    CRRT
    No data in label.
    • Dialyzable? Not expected to be significantly removed by hemodialysis (label).
    • Monitoring Muscle symptoms (myopathy, rhabdomyolysis); renal impairment is a risk factor (label).

    From the Atorvastatin monograph (renalcarematters.com, reviewed).

  • Use: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia… US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Contraindications

  • Active liver disease or unexplained transaminases above 3 times the upper limit
  • Pregnancy, breastfeeding, women of childbearing potential without contraception
  • Glecaprevir/pibrentasvir
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Hypercholesterolemia or mixed dyslipidemia; prevention of cardiovascular events: 10/10 mg to 10/80 mg once daily; titrate at intervals of 4 weeks or more; 2 hours before or 4 hours after a bile acid sequestrant
renalcarematters.com, reviewed

Dosing: Altered kidney function

Neither component needs a kidney dose adjustment: atorvastatin is eliminated in bile and is unaffected by kidney disease, and ezetimibe exposure rises only about 1.5-fold in severe kidney impairment. The Irish label sets no kidney adjustment. Muscle toxicity risk is driven by dose and interacting drugs. It has no US FDA label.

Kidney function measure: SmPC sets no kidney adjustment; pharmacokinetic data use creatinine clearance (CrCl ≤30 mL/min/1.73 m2). Bands shown on CrCl.

Show full dosing details
CrCl ≥60 mL/min
Usual: 10/10 mg once daily; titrate at intervals of 4 weeks or more up to 10/80 mg (SmPC).
CrCl 30–59 mL/min
No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30.
CrCl 15–29 mL/min
No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30. KDIGO 2013 lists atorvastatin 20 mg/day as the dose studied in CKD trials; higher doses are not proven safe in advanced CKD, so avoid high doses at eGFR <30.
CrCl <15 mL/min (not on dialysis)
No dose adjustment in kidney impairment (SmPC). Atorvastatin is unaffected by kidney disease; ezetimibe AUC about 1.5-fold higher at CrCl ≤30. KDIGO 2013 lists atorvastatin 20 mg/day as the dose studied in CKD trials; higher doses are not proven safe in advanced CKD, so avoid high doses at eGFR <30.
Hemodialysis (intermittent)
No label adjustment (atorvastatin unaffected by kidney disease). KDIGO 2013: do not start a statin or statin/ezetimibe in patients already on dialysis; continue it if already taking it at dialysis start.
Peritoneal dialysis
No label adjustment; no PD data. KDIGO 2013: do not start a statin or statin/ezetimibe in patients already on dialysis; continue it if already taking it at dialysis start.
CRRT
No data; usually continued or held per clinical context.
  • Dialyzable? Not stated (both highly protein-bound; removal unlikely).
  • Monitoring Liver function tests before starting and periodically (reduce or stop if transaminases stay above 3 times the upper limit). Creatine kinase if muscle symptoms: do not start if CK is above 5 times the upper limit; stop if above 10 times, or above 5 times with symptoms (SmPC 4.4).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (March 2026). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established in children (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg, 20 mg/10 mg, 40 mg/10 mg

Registered products in the Philippines

16 products registered with the Food and Drug Administration (FDA) Philippines list Atorvastatin + Ezetimibe as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products16
Philippine FDA-registered products for Atorvastatin + Ezetimibe
Package insert
ATOREZEAtorvastatin (as calcium) + Ezetimibe
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc.
DRP-15944-02
Oct 2, 2029
AtorezeAtorvastatin (as calcium) + Ezetimibe
20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Ajanta Pharma Philippines, Inc.Importer: AMB HK Enterprises Inc.
DRP-15945-01
Oct 2, 2029
AtorzetAtorvastatin (as calcium) + Ezetimibe
10 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mediwin PharmaceuticalsIndia
Importer: EuroAsia Pharmaceuticals Inc.Trader: Tunic Healthcare
DRP-7785
Jul 21, 2032
Atorzet 20Atorvastatin (as calcium) + Ezetimibe
40 mg / 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
Euroasia Pharmaceuticals, Inc.
DR-XY48270
Aug 10, 2027
AtozetEzetimibe + Atorvastatin (As Calcium)
10mg/80mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's), Physician Sample: Alu/Alu Blister Pack x 10's (Box of 10's)
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Organon (Philippines) Incorporated
DR-XY46092
Oct 8, 2031
AvamedAtorvastatin (as calcium) + Ezetimibe
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Pharma Hub CorporationImporter: AMB HK Enterprises Inc.
DRP-15944-03
Oct 2, 2029
AvamedAtorvastatin (as calcium) + Ezetimibe
20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Pharma Hub CorporationImporter: AMB HK Enterprises Inc.
DRP-15945-03
Oct 2, 2029
AVATOR MAXAtorvastatin (as calcium) + Ezetimibe
20mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt Ltd.India
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-15945-04
Oct 2, 2029
AVATOR PLUSAtorvastatin (as calcium) + Ezetimibe
10mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt Ltd.India
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-15944-04
Oct 2, 2029
EztorAtorvastatin (as calcium) + Ezetimibe
10 mg/10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15944
Oct 2, 2029
EztorAtorvastatin (as calcium) + Ezetimibe
20 mg/10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. LtdIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15945
Oct 2, 2029
LiptruzetEzetimibe + Atorvastatin (as calcium)
10mg/10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample)
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Organon (Philippines) Incorporated
DR-XY46089
Oct 8, 2031
LiptruzetEzetimibe + Atorvastatin (as calcium)
10mg/20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample)
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Organon (Philippines) Incorporated
DR-XY46090
Oct 8, 2031
LiptruzetEzetimibe + Atorvastatin (as calcium)
10mg/40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) (Physician’s Sample)
RxVAT-exempt
MSD International GmbH (Singapore Branch)Singapore
Organon (Philippines) Incorporated
DR-XY46091
Oct 8, 2031
Torezib 10Atorvastatin (as calcium) + Ezetimibe
10 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc.
DRP-15944-01
Oct 2, 2029
Torezib 20Atorvastatin (as calcium) + Ezetimibe
20 mg/10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc.
DRP-15945-02
Oct 2, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Glecaprevir/pibrentasvirAvoidLarge rise in statin exposure.Contraindicated.
Fusidic acid (systemic)AvoidRhabdomyolysis, including deaths.Contraindicated; restart statin 7 days after the last fusidic acid dose.
Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole), tipranavir/ritonavirAvoidHigher atorvastatin levels; myopathy.Avoid; if unavoidable use lower doses (tipranavir/ritonavir: maximum 10/10 mg).
Elbasvir/grazoprevir, boceprevirAdjust or monitorHigher atorvastatin levels.Maximum 10/20 mg.
Moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil, fluconazole)Adjust or monitorHigher atorvastatin levels.Lower maximum dose; monitor.
Gemfibrozil, fenofibrateAvoidMyopathy risk.Not recommended.
CyclosporineAdjust or monitorHigher ezetimibe and atorvastatin levels.Use with caution; monitor cyclosporine levels.
Warfarin and other coumarinsAdjust or monitorINR change.Monitor INR.
ColchicineAdjust or monitorMyopathy reported.Use with caution.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Diarrhea
  • Myalgia

Serious

  • Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy
  • Hepatic failure
  • Anaphylaxis; Stevens-Johnson syndrome, toxic epidermal necrolysis
  • Myasthenia gravis
renalcarematters.com, reviewed

Monitoring parameters

  • Liver function tests before starting and periodically (reduce or stop if transaminases stay above 3 times the upper limit). Creatine kinase if muscle symptoms: do not start if CK is above 5 times the upper limit; stop if above 10 times, or above 5 times with symptoms (SmPC 4.4). Kidney
  • Liver tests before starting and periodically
  • CK if muscle symptoms
  • Lipids at 4 weeks or more after a dose change
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Half-lifeEzetimibe about 22 hours; atorvastatin about 14 hours (inhibitory activity 20 to 30 hours)
Half-life in kidney failure (ESKD) kidneyAtorvastatin unaffected; ezetimibe AUC about 1.5-fold at CrCl ≤30
Metabolism (CYP, transporters)Ezetimibe glucuronidated; atorvastatin CYP3A4
Active metabolitesEzetimibe glucuronide; atorvastatin hydroxy metabolites
Renal excretion kidneyEzetimibe 11% in urine (78% feces); atorvastatin mainly biliary
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Ezetimibe/Atorvastatin Krka 10/20 mg SmPC (PA1347/116/002) [HPRA (Ireland) product information, March 2026; no US FDA label]. https://assets.hpra.ie/products/Human/41397/Licence_PA1347-116-002_02032026141340.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. KRKA, d.d.. (2026). Ezetimibe/Atorvastatin Krka 10 mg/20 mg film-coated tablets [Summary of product characteristics, licence PA1347/116/002; text revised March 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/41397/Licence_PA1347-116-002_02032026141340.pdf
  4. Wanner, C., & Tonelli, M. (2014). KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney International, 85(6), 1303–1309. https://doi.org/10.1038/ki.2014.31

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .